Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan GlobeNewswire - Mon Jun 29, 7:30AM CDT CMTX - Mon Jun 29, 7:30AM CDT
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy's off-target effects --
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares GlobeNewswire - Wed Jun 10, 8:54AM CDT CMTX - Wed Jun 10, 8:54AM CDT
Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional...
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire - Thu Jun 4, 8:22AM CDT CMTX - Thu Jun 4, 8:22AM CDT
Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross...
Aileron Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire - Wed Jun 3, 3:01PM CDT CMTX - Wed Jun 3, 3:01PM CDT
Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to...
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics Zacks Equity Research - Zacks Investment Research - Tue Jun 2, 9:22AM CDT Zacks Equity Research - ZACKS - Tue Jun 2, 9:22AM CDT
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
Thinking about buying stock in Ovid Therapeutics, Celsion Corp, Aileron Therapeutics, Cronos Group, or Bank of America? PR Newswire - PRF - Mon Jun 1, 8:31AM CDT CMTX - Mon Jun 1, 8:31AM CDT
, /PRNewswire/ --Â InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.
5 Top Stocks Up 100%+ in May With More Room to Run Tirthankar Chakraborty - Zacks Investment Research - Mon Jun 1, 7:34AM CDT Tirthankar Chakraborty - ZACKS - Mon Jun 1, 7:34AM CDT
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent GlobeNewswire - Wed May 27, 7:30AM CDT CMTX - Wed May 27, 7:30AM CDT
Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients...
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire - Mon May 11, 7:30AM CDT CMTX - Mon May 11, 7:30AM CDT
Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020 GlobeNewswire - Wed Apr 22, 7:30AM CDT CMTX - Wed Apr 22, 7:30AM CDT
Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire - Mon Mar 30, 10:05PM CDT CMTX - Mon Mar 30, 10:05PM CDT
Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data...
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer GlobeNewswire - Wed Dec 18, 7:30AM CST CMTX - Wed Dec 18, 7:30AM CST
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and...
Aileron Therapeutics Reports Third Quarter 2019 Results GlobeNewswire - Thu Nov 7, 6:30AM CST CMTX - Thu Nov 7, 6:30AM CST
Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer's IBRANCE(R) (palbociclib) for the treatment of patients with tumors harboring...
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th GlobeNewswire - Thu Oct 31, 7:30AM CDT CMTX - Thu Oct 31, 7:30AM CDT
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m....
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference GlobeNewswire - Tue Oct 29, 7:00AM CDT CMTX - Tue Oct 29, 7:00AM CDT
Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th GlobeNewswire - Mon Oct 21, 7:00AM CDT CMTX - Mon Oct 21, 7:00AM CDT
Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent GlobeNewswire - Wed Oct 16, 7:30AM CDT CMTX - Wed Oct 16, 7:30AM CDT
Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology GlobeNewswire - Sat Sep 28, 6:30AM CDT CMTX - Sat Sep 28, 6:30AM CDT
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing...
